相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1767
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- The University of Oklahoma Health Campus convened its first AI Symposium to map how artificial intelligence can improve care, research and education across the state. - OU leaders cited Oklahoma's ranking of 49th in many health outcomes, with high rates of diabetes, cancer, cardiovascular and behavioral health conditions, as motivation for AI-driven innovation. - Clinical AI is already deployed for triaging medical images, clinician documentation, patient risk prediction and estimating hospital readmission likelihood, with clinicians retaining oversight. - Officials set a five-year horizon to move key health indicators and emphasized building data infrastructure, governance and AI literacy into physician training.
- Columbia University Irving Medical Center and Amazon Web Services have launched a collaborative agreement to support development and commercialization of biomarkers and diagnostics for disease. - AWS will supply cloud computing, artificial intelligence, machine learning and high-performance computing access so Columbia researchers can analyze large complex datasets and build predictive models. - The collaboration spans early-career faculty pursuing biomarker discovery, faculty conducting sponsored research and proof-of-concept studies, and faculty building startups from their discoveries. - AWS will also build a secure online research portal meeting CUIMC's biomedical research, security and compliance requirements, and fund the Center for Innovation in Imaging Biomarkers and Integrated Diagnostics & AWS Junior Scholars program.
- EchoNext, developed at NewYork-Presbyterian and Columbia University, is the first FDA-cleared AI tool that reads standard 12-lead ECGs to flag six types of structural heart disease. - In a head-to-head study, EchoNext identified 77% of structural heart problems versus 64% accuracy by cardiologists, and was trained on over 700,000 ECG-echocardiogram pairs. - Nature Medicine published the first peer-reviewed case where AI detection of undiagnosed heart failure by EchoNext led to a heart transplant. - Pathway Labs announced an $8.5 million seed round and a partnership with OpenEvidence to deploy the tool across a platform used by over 500,000 U.S. clinicians.
- Columbia University's Irving Institute received a seven-year, $75 million Clinical and Translational Science Award from NCATS at NIH, marking its fifth consecutive CTSA grant since 2006. - The funding will launch a first-of-its-kind pilot program using AI-assisted tools and community health workers to return individual research results to study participants. - New investments will enhance AI and data science capabilities including a tri-institutional Data Lake House, federated learning infrastructure, and clinical data phenotyping tools. - The grant brings total NIH CTSA Program funding to Columbia to $288 million over two decades, supporting translational science from bench to bedside.
- Boston Scientific's FRACTURE IDE trial demonstrated that the SEISMIQ 4CE Coronary Intravascular Lithotripsy Catheter achieved 93.3% freedom from major adverse cardiac events at 30 days, exceeding the prespecified performance goal. - The device showed 93.7% procedural success rate and achieved 100% successful stent delivery in 420 patients with severely calcified coronary artery disease. - The trial results support regulatory submission for the investigational device, which uses laser energy to generate acoustic pressure waves that fracture calcium deposits in coronary arteries. - Moderate-to-severe coronary calcification affects nearly one-third of patients undergoing percutaneous coronary intervention, presenting significant procedural challenges and complication risks.
- Emboline's PROTECT H2H trial enrolled 522 patients and became the first randomized IDE study of an embolic protection device in TAVR to meet all primary and secondary safety and efficacy endpoints. - The Emboliner system demonstrated statistical superiority in debris capture (93 vs. 31 particles ≥150μm; p < 0.0001) and significantly higher technical success rates (95.9% vs. 87.1%; p = 0.0005) compared to Boston Scientific's Sentinel CPS control device. - The device achieved non-inferiority for key safety endpoints including 30-day MACCE (4.5% vs. 5.0%) and stroke rates (2.0% vs. 2.1%), while providing comprehensive cerebral and systemic embolic protection during transcatheter aortic valve replacement procedures.
- JenaValve's Trilogy transcatheter heart valve system received FDA premarket approval as the first and only transcatheter device approved for treating symptomatic, severe aortic regurgitation in high-risk patients. - The approval was supported by the ALIGN-AR pivotal trial involving 180 high-risk patients, demonstrating effective orifice area, low transvalvular gradients, and low paravalvular regurgitation. - The Trilogy system features proprietary radiopaque locators that attach directly to native aortic leaflets, enabling secure implantation even without calcium deposits typically required by conventional TAVR valves. - JenaValve plans immediate launch activities with participating clinical study sites, addressing a significantly undertreated condition affecting tens of thousands of patients annually in the United States.
- The ALL-RISE trial, involving 1,930 patients across 59 global sites, demonstrated that CathWorks FFRangio met non-inferiority to invasive pressure wire guidance for major adverse cardiac events at one year. - FFRangio showed a primary endpoint event rate of 6.9% compared to 7.1% for the pressure wire group, with improved resource utilization including reduced radiation exposure and shorter procedure times. - A separate US Medicare study of over 4,000 patients showed comparable clinical outcomes through 2 years, with ADP utilization growing nearly 8-fold between 2019 and 2024. - The technology combines artificial intelligence and computational science to obtain physiologic information from routine angiograms, eliminating the need for drug stimulation and invasive pressure wires.
- TScan Therapeutics will present two-year relapse data from its ALLOHA Phase 1 trial showing 82% of patients treated with TSC-101 remained relapse-free compared to 64% in the control arm. - The company has reached agreement with FDA on a registrational path forward for TSC-101 as a treatment for acute myeloid leukemia and myelodysplastic syndromes. - A pivotal trial for TSC-101 is scheduled to launch in the second quarter of 2026, utilizing an improved commercial-ready manufacturing process. - TSC-101 demonstrated favorable safety profile and durable long-term persistence with TCR-T cells detected more than two years post-infusion.
- A double-blind clinical trial with 240 participants in Gambia, Kenya, and Brazil confirms ivermectin can be safely administered to children weighing as little as 5 kilograms (11 pounds). - The study found only one serious adverse event—a transient liver enzyme increase that resolved after 32 days—with all other treatment-related events being mild and self-limiting. - This finding could significantly expand mass drug administration campaigns against neglected tropical diseases, as current manufacturer labeling restricts ivermectin use to children over 15 kilograms. - Including small children in ivermectin campaigns could improve treatment coverage for intestinal worms, scabies, river blindness, and potentially enhance malaria transmission suppression efforts.
